127 related articles for article (PubMed ID: 33872566)
1. Oncogene targeted therapy for metastatic primary scrotal melanoma.
Stocks B; Fuentes H; McDowell Z; Brooks M; Jones JA
Can J Urol; 2021 Apr; 28(2):10643-10647. PubMed ID: 33872566
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
3. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
Ponti G; Tomasi A; Pellacani G
J Hematol Oncol; 2012 Oct; 5():60. PubMed ID: 23031422
[TBL] [Abstract][Full Text] [Related]
4. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
6. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
Wilgenhof S; Neyns B
J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
[No Abstract] [Full Text] [Related]
7. Dabrafenib in the treatment of advanced melanoma.
Medina T; Amaria MN; Jimeno A
Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
[TBL] [Abstract][Full Text] [Related]
8. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib: first global approval.
Ballantyne AD; Garnock-Jones KP
Drugs; 2013 Aug; 73(12):1367-76. PubMed ID: 23881668
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
15. NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Tucker H; Umeweni N; Robertson J; Adam J
Lancet Oncol; 2014 Dec; 15(13):1425-1426. PubMed ID: 25499274
[No Abstract] [Full Text] [Related]
16. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
17. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
18. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
19. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
Lim J; Lomax AJ; McNeil C; Harrisberg B
Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
[TBL] [Abstract][Full Text] [Related]
20. Successful desensitization protocol for hypersensitivity reaction probably caused by dabrafenib in a patient with metastatic melanoma.
Bar-Sela G; Abu-Amna M; Hadad S; Haim N; Shahar E
Jpn J Clin Oncol; 2015 Sep; 45(9):881-3. PubMed ID: 26056325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
